Kyowa Hakko Kirin : Launch of LUMICEF® for Psoriasis Treatment, in Japan
September 27, 2016 at 02:05 am EDT
Share
September 27, 2016
Tokyo, Japan, September 27, 2016 --- Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, 'Kyowa Hakko Kirin') announced today that LUMICEF Subcutaneous Injection 210 mg Syringe will be launched in Japan on September 30, 2016.
LUMICEF is a novel fully human anti-interleukin-17 (IL-17) receptor A antibody that inhibits biological activity of IL-17A, IL-17F and other IL-17s. LUMICEF was listed on the National Health Insurance (NHI) Drug Price List on August 31 , 2016 after the manufacturing and marketing approval in Japan on July 4 , 2016. LUMICEF is expected to improve the clinical symptoms of patients with the approved indications.
'We are very pleased to announce the launch of LUMICEF in Japan, the first launch worldwide' said Hiroshi Sugitani, Managing Executive Officer, Vice President Head of Sales & Marketing Division of Kyowa Hakko Kirin. 'We believe that LUMICEF will provide a new therapeutic option for the treatment of psoriasis and will greatly contribute to better improvement of treatment satisfaction and improved QOL (quality of life) in patients with psoriasis'.
The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.
(Product information)
Product Name
LUMICEF Subcutaneous Injection 210 mg Syringe
Generic Name
Brodalumab (Genetical Recombination)
Indications
The following diseases that respond inadequately to existing therapies; Psoriasis vulgaris, psoriatic arthritis, pustular psoriasis, and psoriatic erythroderma.
Dosage and administration
In adults, administer 210 mg subcutaneously as brodalumab (Genetical Recombination) at Weeks 0, 1, and 2, followed by 210 mg every 2 weeks.
Package
LUMICEF Subcutaneous Injection 210 mg / 1 Syringe
Date of approval
July 4 , 2016
Date of NHI price listing
August 31 , 2016
NHI drug price
73,158 Yen / 1 Syringe
About Psoriasis
Psoriasis is a chronic skin disorder. Typical symptoms include systemic erythema with clearly demarcated lesions, induration and hyperplasia inducing silver white plaques on the skin. Itching, inflammatory arthritis and abnormal nail morphology may also manifest.
About IL-17 receptor A
Interleukin-17 receptor A is a component of the receptor for IL-17A, IL-17A/F, IL-17F and IL-17C. These pro-inflammatory cytokines are thought to contribute to the pathophysiology associated with psoriasis.
About IL-17
IL-17A, IL-17F and other IL-17s are pro-inflammatory cytokines thought to be involved in autoimmune diseases including psoriasis.
Kyowa Hakko Kirin Co. Ltd. published this content on 27 September 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 27 September 2016 06:05:10 UTC.
Original documenthttp://www.kyowa-kirin.com/news_releases/2016/e20160927_01.html
Public permalinkhttp://www.publicnow.com/view/F0380C899F42579AC101EA5AB8981188A5CCE847
Kyowa Kirin Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows:
- sales of pharmaceutical products (92.6%): prescription products for anemia, cancers, immune and nephrology diseases treatment;
- sales of licenses (7.4%).
At the end of 2021, the group had 3 production sites located in Japan (2) and China.
Net sales break down geographically as follows: Japan (60.9%), Asia (9%), Americas (16.3%) and Europe (13.8%).